PBA
JBIO

Paradigm Biocapital Advisors’s Jade Biosciences JBIO Stock Holding History

Paradigm Biocapital Advisors’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$63.5M Buy
+2,857,405
New +$59.6M 1.19% 18
2024
Q1 		– Sell
-4,092
Closed -$3.24M – 35
2023
Q4 		$3.24M Buy
+4,092
New +$2.09M 0.15% 29

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Paradigm Biocapital Advisors's JBIO Position: Q2 2026 in Review

Paradigm Biocapital Advisors opened a new position in Jade Biosciences (JBIO) in Q2 2026: 2,857,405 shares worth $63.5M. The stake represents 1.19% of the portfolio and ranks #18 among its holdings. This is a return to the name: Paradigm Biocapital Advisors previously reported a position in JBIO as recently as Q4 2023.

Paradigm Biocapital Advisors first reported a position in JBIO in Q4 2023 and has held it in 2 quarters since. 154 funds tracked by Wall St. Rank hold JBIO as of Q2 2026.

  • Paradigm Biocapital Advisors held 2,857,405 shares of Jade Biosciences worth $63.5M as of Q2 2026.
  • Jade Biosciences was a new Paradigm Biocapital Advisors position in Q2 2026.
  • Jade Biosciences made up 1.19% of Paradigm Biocapital Advisors's portfolio in Q2 2026, its #18 holding.
  • Paradigm Biocapital Advisors first reported a position in Jade Biosciences in Q4 2023 and has held it in 2 quarters since.
  • 154 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2026.

Based on Paradigm Biocapital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.